Case Study Download 🎓📂 A 77-year-old female presented with angina symptoms, multivessel coronary artery disease (CAD) and a moderately depressed ejection fraction (40%). Past history included severe CAD with prior coronary bypass graft surgery (CABG), with no available grafts

Today Carlos Mercado celebrates 3 years of #HeartRecovery. Learn about his journey:

Planning to be in Boston for #ISHLT2025? J&J MedTech would like to personally invite you to our evening reception during ISHLT at the Boston Public Library. Please join us to build meaningful connections and hear more about our purposefully driven Heart Recovery innovations

Register now for the Heart Recovery Innovation Suite Sessions at #ISHLT2025! bit.ly/44pSkij

If you're attending #ISHLT2025 this year, join us for a special symposium: Advancing the Science of Heart Recovery: Lessons Learned from SURPASS Study and DanGer Shock Trial. Speakers will include Navin Kapur, M.D., Jacob Møller, M.D., David A. D'Alessandro, M.D., Marwan F.

Stop booth #325 at #ISHLT2025 to learn more about our purposefully driven Heart Recovery innovations. heartrecovery.com/en-us

We're heading to Seattle for the AATS 105th Annual Meeting! Join J&J MedTech at Booth 1305 from May 2–5 at the Seattle Convention Center to explore innovations supporting thoracic and cardiovascular care. May 2–5, 2025 Booth 1305 | Seattle Convention Center | Summit #AATS2025

The #SCAI2025 Scientific Sessions are coming up! Join us May 1-3 in Washington, D.C. and visit Booth 310 to learn more about Impella. Our team will be there to connect and discuss the latest in #HeartRecovery. Walter E. Washington Convention Center | May 1-3

Don't miss "Life in the Post DanGer Shock Era: Optimizing Guideline Driven Care" at this year's #SCAI2025 Scientific Sessions. Lunch will be served. We hope to see you there! Thursday, May 1 | 12:15 - 1:15 p.m. Walter E. Washington Convention Center, Room 152AB

The doors are open at #AATS2025 — and we’re ready to welcome you at Booth 1305! Stop by to explore how Impella and our advanced patient management solutions are impacting outcomes in cardiothoracic care. We’re here through May 5 — let’s talk #HeartRecovery.

It was wonderful to see so much great Impella education happening at #SCAI2025, with many interesting conversations happening at our "Life in the Post DanGer Shock Era: Optimizing Guideline Driven Care" symposia and during other SCAI sessions.

Thank you to everyone who visited our booth at #AATS2025! If you're interested in learning more about Impella you can find lots of helpful information on our site: heartrecovery.com/en-us

This week is #EMSWeek! Did you know that we have educational materials for EMS professionals who transport Impella patients available on our website? Learn more: bit.ly/4k0NFbw

If you take care of Impella patients and have questions about positioning, watch this: Jo Kajewski, Advanced Impella Trainer, gives an in-depth look at managing Impella positioning using imaging.

Samin Sharma, MD, senior author of “Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry," sat down with the Heart Recovery team's Seth Bilazarian, MD, to discuss his algorithm for selecting cases for Protected

Learn how Impella is designed to maximize blood compatibility, what factors can contribute to hemolysis in the clinical setting, and more with our hemolysis FAQ: heartrecovery.com/en-us/educatio…

Revisiting the basics of my favourite MCS device. Ex-vivo training to prevent In-Vivo complications! #Impella #MCS #interventionalcardiology Mount Sinai Fuster Heart Hospital Johnson & Johnson MedTech | Heart Recovery Johnson & Johnson MedTech | HeartRecovery for HCPs Cardiology Fellows at Mount Sinai Morningside

In a recent Thursday Night Live, a multidisciplinary team of physicians from Hackensack University Medical Center discussed how the DanGer Shock RCT validated their cardiogenic shock team and protocols. Watch the full discussion here: bit.ly/45gY7HF

Today we celebrate an important and exciting milestone as the PROTECT IV study completes enrollment with 1252 subjects randomized! This achievement would not have been possible without the support of each PROTECT IV site. We value and appreciate your collective contributions to

Find answers to common questions about the New England Journal of Medicine DanGer Shock RCT: lnkd.in/ejWuM8jN